Stocks Health care VXRT
OTC · Health careVaxart, Inc. (VXRT)
Vaxart, Inc. brought in $243.1M of revenue over the twelve months to June 30, 2026, up 201.1% from a year earlier. Net income was $38.6M, a net margin of 15.9%. Operating cash flow minus capital spending left $7.6M of free cash flow in fiscal 2025. At June 30, 2026 it held $50.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Watch VXRT in 60 secondsWhat Vaxart, Inc. does
Vaxart, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker VXRT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $237.3M | $16.3M | $0.07 | $7.6M |
| 2024 | $28.7M | -$66.9M | -$0.33 | -$45.3M |
| 2023 | $7.4M | -$82.5M | -$0.57 | -$72.3M |
| 2022 | $107K | -$107.8M | -$0.84 | -$104.4M |
| 2021 | $892K | -$70.5M | -$0.58 | -$65M |
| 2020 | $4M | -$32.2M | -$0.36 | -$25M |
Full financial statements: income, balance sheet and cash flow
Where VXRT ranks in Health care
Latest SEC filings
What Vaxart, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026Other event 8-K
- August 25, 2026Other event 8-K
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 32% to $27.2M versus the same quarter last year; diluted EPS -$0.06 versus -$0.07.
- August 6, 2026
- July 28, 2026Other event 8-K
- July 17, 2026
- July 7, 2026Other event 8-K
- July 6, 2026Additional proxy material DEFA14A
- July 2, 2026Additional proxy material DEFA14A
- July 2, 2026Form DFAN14A filing DFAN14A
What is VXRT worth? A DCF from its reported cash flow
Insider trades
What the people running Vaxart, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 5 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 16, 2026 | Finney KevinDirector | Received as pay | 39,400 | - |
| July 16, 2026 | Wheadon David E.Director | Received as pay | 39,400 | - |
| July 16, 2026 | Watson W. MarkDirector | Received as pay | 39,400 | - |
| July 16, 2026 | Heron Elaine JDirector | Received as pay | 39,400 | - |
| July 16, 2026 | Breitmeyer James BDirector | Received as pay | 8,315 | - |
| May 22, 2026 | Watson W. MarkDirector | Bought | 10,000 | $6.5K |
| May 19, 2026 | Grasman Jeroen NicolaasChief Financial Officer | Shares withheld for tax | 31,395 | $19.2K |
| April 23, 2026 | Breitmeyer James BDirector | Received as pay | 78,800 | - |
| March 28, 2026 | Tucker SeanSVP, Chief Scientific Officer | Shares withheld for tax | 3,924 | $2.6K |
Who owns VXRT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
7 insiders reported holding 2,155,343 shares in total, about $978.5K at the last price.
| Holder | Shares |
|---|---|
| Tucker SeanSVP, Chief Scientific Officer | 882,811 |
| Grasman Jeroen NicolaasChief Financial Officer | 545,605 |
| Finney KevinDirector | 244,171 |
| Watson W. MarkDirector | 173,525 |
| Heron Elaine JDirector | 135,966 |
| Breitmeyer James BDirector | 87,115 |
| Wheadon David E.Director | 86,150 |
Questions about VXRT
What does Vaxart, Inc. do?
Vaxart, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker VXRT.
Is Vaxart, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $38.6M on revenue of $243.1M, a net margin of 15.9%.
How much revenue does Vaxart, Inc. make?
Over the twelve months to June 30, 2026 Vaxart, Inc. reported revenue of $243.1M. That is 201.1% more than a year earlier.
When did Vaxart, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 14, 2026.
Similar companies
Compare VXRT with
Follow VXRT
Get an email when Vaxart, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow VXRT: get an email when it filesWhere the numbers come from
Financial figures are the values Vaxart, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.